ScholarIQanswers from OpenAlex & ORCID
Ugo De Giorgi
ResearcherPublications, citations & collaboration network
Ugo De Giorgi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ugo De Giorgi have?
ScholarIQindexed works
Ugo De Giorgi has 974 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ugo De Giorgi have?
ScholarIQcitation count
Ugo De Giorgi has 30,659 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ugo De Giorgi?
ScholarIQh-index
Ugo De Giorgi has an h-index of 81 in OpenAlex.
What is the i10-index of Ugo De Giorgi?
ScholarIQi10-index
Ugo De Giorgi has an i10-index of 388 in OpenAlex.
What is the ORCID of Ugo De Giorgi?
ScholarIQorcid
The ORCID for Ugo De Giorgi is on the source record.
What is the OpenAlex record for Ugo De Giorgi?
ScholarIQopenalex
The OpenAlex for Ugo De Giorgi is on the source record.
What are the most-cited papers on Ugo De Giorgi?
ScholarIQmost cited works
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, David Cella, James A. Reeves, Robert D. Hawkins, Jun Guo, Paul Nathan, Michael Staehler, Paul de Souza, Jaime R. Merchan, Ekaterini Boleti, Kate Fife, Jie Jin, Robert J. Jones, Hirotsugu Uemura, Ugo De Giorgi, Ulrika Harmenberg, Jinwan Wang, Cora N. Sternberg, Keith C. Deen, Lauren McCann, Michelle D. Hackshaw, Rocco J. Crescenzo, Lini Pandite, Toni K. Choueiri
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Neeraj Agarwal, Arun Azad, Joan Carles, André P. Fay, Nobuaki Matsubara, Daniel Heinrich, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, Karim Fizazi
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia